Estrella Immunopharma Appoints Dr. Cheng Liu as CEO
Company Announcements

Estrella Immunopharma Appoints Dr. Cheng Liu as CEO

Estrella Immunopharma ( (ESLA) ) just unveiled an update.

Estrella Immunopharma, Inc. has appointed Dr. Cheng Liu as Director, President, and CEO with an ‘at will’ employment agreement offering a $250,000 annual salary, bonus potential, and equity incentives. The contract allows flexibility for termination and offers severance packages based on the circumstances, highlighting the company’s strategic focus on aligning leadership performance with financial and operational goals.

Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyEstrella achieves CR in patient treated with CD19-redirected ARTEMIS T-cells
TipRanks Auto-Generated NewsdeskEstrella Immunopharma Welcomes New Chairperson, Expands Board
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App